801 related articles for article (PubMed ID: 27173342)
1. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
2. [Effect of electroacupuncture intervention on levels of SOD, GSH, GSH-Px, MDA, and apoptosis of dopaminergic neurons in substantia Nigra in rats with Parkinson's disease].
Li J; Wang LN; Xiao HL; Li X; Yang JJ
Zhen Ci Yan Jiu; 2014 Jun; 39(3):185-91. PubMed ID: 25069193
[TBL] [Abstract][Full Text] [Related]
3. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
4. [Effect of electroacupuncture stimulation of "Fengfu" (GV 16) and "Taichong" (LR 3) on expression of COX-2 and tyrosine hydroxylase in Substantia Nigra in rats with Parkinson's disease].
Wang SJ; Fang JQ; Ma J; Zhou D; Wang YC; Gan SY; Sun GJ
Zhen Ci Yan Jiu; 2013 Jun; 38(3):198-201. PubMed ID: 24006664
[TBL] [Abstract][Full Text] [Related]
5. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
Wang S; Qi XJ; Han D
Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
[TBL] [Abstract][Full Text] [Related]
6. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
7. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
[TBL] [Abstract][Full Text] [Related]
9. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.
Charlton CG; Mack J
Mol Neurobiol; 1994; 9(1-3):149-61. PubMed ID: 7888091
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
Cai T; Wei C; Zhai S; Tai S; Zhang C; Jiao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jan; 34(1):35-40. PubMed ID: 29595455
[TBL] [Abstract][Full Text] [Related]
11. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
13. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
14. Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD).
Sheikh MA; Malik YS; Xing Z; Guo Z; Tian H; Zhu X; Chen X
Acta Biomater; 2017 May; 54():58-68. PubMed ID: 28025049
[TBL] [Abstract][Full Text] [Related]
15. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.
Kastner A; Hirsch EC; Agid Y; Javoy-Agid F
Brain Res; 1993 Mar; 606(2):341-5. PubMed ID: 8098254
[TBL] [Abstract][Full Text] [Related]
17. The hTH-GFP reporter rat model for the study of Parkinson's disease.
Iacovitti L; Wei X; Cai J; Kostuk EW; Lin R; Gorodinsky A; Roman P; Kusek G; Das SS; Dufour A; Martinez TN; Dave KD
PLoS One; 2014; 9(12):e113151. PubMed ID: 25462571
[TBL] [Abstract][Full Text] [Related]
18. [Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Pastukhov IuF; Chesnokova AIu; Iakimchuk AA; Ekimova IV; Romanova IV; Khudik KA
Ross Fiziol Zh Im I M Sechenova; 2010 Dec; 96(12):1190-202. PubMed ID: 21473106
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.
Zhou L; Wang ZY; Lian H; Song HY; Zhang YM; Zhang XL; Fan RF; Zheng LF; Zhu JX
Biochem Biophys Res Commun; 2014 Sep; 452(3):560-6. PubMed ID: 25172664
[TBL] [Abstract][Full Text] [Related]
20. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Stott SRW; Barker RA
Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
